Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review.BJC reports · 2025
   Article
2. Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.Therapeutic advances in medical oncology · 2025
   Review
3. Evolution of the Development of PARP Inhibitors.Cancer treatment and research · 2023
   Article
4. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.Clinical pharmacokinetics · 2022
   Review
5. Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy.Cancers · 2022
   Article
6. Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.NPJ breast cancer · 2022
   Article
7. The Role of Poly(ADP-Ribose) Polymerase-1 in Cutaneous Wound Healing.Advances in wound care · 2019
   Review
8. Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
   Article
9. Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer.Oncology letters · 2018
   Review
10. Rucaparib: a novel PARP inhibitor forDrug design, development and therapy · 2018
    Review
11. Chemoresistance and targeted therapies in ovarian and endometrial cancers.Oncotarget · 2017
    Review
12. Emerging treatment options for ovarian cancer: focus on rucaparib.International journal of women's health · 2017
    Review
13. PARP inhibitors: the race is on.British journal of cancer · 2016
    Article

Corrections and comments

• Erratum for
  Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.2016

Authors and funding

17 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.